Comment: If you have a less worn out

(See in situ)

In reply to comment: If pharmaceutical patenting (see in situ)

If you have a less worn out

If you have a less worn out pro-IP(for pharmaceuticals) argument that is not based on monopoly incentives, I would actually be interested in hearing it.